June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Aflibercept for AMD patients treated unsuccessfully with Ranibizumab and Bevacizumab
Author Affiliations & Notes
  • George Dimitris Pappas
    Ophthalmology, Venizeleio Hospital of Crete, Heraklion, Greece
  • Footnotes
    Commercial Relationships George Pappas, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1505. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      George Dimitris Pappas; Aflibercept for AMD patients treated unsuccessfully with Ranibizumab and Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1505.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the Aflibercept efficacy in AMD patients where Ranibizumab and Bevacizumab failed to treat them successfully.

Methods: 24 AMD patients, previously unsuccessfully treated with Ranibizumab and Bevacizumab assigned for treatment with Aflibercept. The mean number of previous injections was 9 of both agents in order to avoid tachyphylaxis. Visual Acuity, Central Macular Thickness (CMT) and side effects were evaluated. The mean CMT prior to Aflibercept introduction was 384μm (SD 55.10). The follow up period was 6 months

Results: Mean reductin in CMT was 50.8μm (p<0.01). 16 of the 24 patients improved VA by a mean of 3 letters. For the 16 patients with the increased VA the mean CMT reduction was 84.4μ ( p<0.001).

Conclusions: We believe that Aflibercept is a potent agent and can improve VA in patients where other anti-VEGF agents fail to achieve it.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.